KalVista Pharmaceuticals, Inc.
KALV
$14.66
$1.148.43%
NASDAQ
| 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.12M | 1.43M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.12M | 1.43M | -- | -- | -- |
| Cost of Revenue | 57.46M | 62.92M | 73.78M | 83.14M | 93.07M |
| Gross Profit | -42.34M | -61.49M | -73.78M | -83.14M | -93.07M |
| SG&A Expenses | 160.69M | 138.97M | 111.89M | 95.95M | 76.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.15M | 201.89M | 185.67M | 179.09M | 169.30M |
| Operating Income | -203.03M | -200.46M | -185.67M | -179.09M | -169.30M |
| Income Before Tax | -202.61M | -194.37M | -176.87M | -168.44M | -153.20M |
| Income Tax Expenses | 7.71M | 5.55M | 3.39M | 4.25M | -- |
| Earnings from Continuing Operations | -210.31 | -199.92 | -180.26 | -172.69 | -153.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -210.31M | -199.92M | -180.26M | -172.69M | -153.20M |
| EBIT | -203.03M | -200.46M | -185.67M | -179.09M | -169.30M |
| EBITDA | -202.00M | -199.50M | -184.73M | -178.20M | -168.43M |
| EPS Basic | -3.95 | -3.87 | -3.62 | -3.66 | -3.57 |
| Normalized Basic EPS | -2.40 | -2.37 | -2.24 | -2.25 | -2.25 |
| EPS Diluted | -3.95 | -3.87 | -3.62 | -3.66 | -3.57 |
| Normalized Diluted EPS | -2.40 | -2.37 | -2.24 | -2.25 | -2.25 |
| Average Basic Shares Outstanding | 213.06M | 205.77M | 198.51M | 189.05M | 171.14M |
| Average Diluted Shares Outstanding | 213.06M | 205.77M | 198.51M | 189.05M | 171.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |